Citations

Showing 10 of 108081 citations.

Top Ten Tips Palliative Care Clinicians Should Know About Delivering Specialty-Aligned Palliative Care
Leiter, Richard E. , Bischoff, Kara , Carey, Elise C. , Gelfand, Samantha L. , Iyer, Anand , Jain, Nelia , Kramer, Neha M. , Lally, Kate , Landzberg, Michael J., Lever, Natasha, Newport, Kristina , O’Donnell, Arden , Sciacca, Kate, Snaman, Jennifer M. , Tulsky, James A. , Rosa, William E. , Bischoff, Kara E , Iyer, Anand S , Tulsky, James A , Rosa, William E , Patel, Arpan , Lakin, Joshua R.

Mayo Clinic

Journal of Palliative Medicine | March 31, 2023 | Volume: 26 | Issue: 10 | Pages: 1401-1407

10.1089/jpm.2023.0116 | PMID 37001173 Get It

Use of Artificial Intelligence for Digital Breast Tomosynthesis Screening: A Preliminary Real-world Experience
Letter, Haley , Peratikos, Meridith, Toledano, Alicia Y. , Hoffmeister, Jeffrey W. , Nishikawa, Robert M. , Shisler, Julie , Maimone, Santo , Villegas, Hector Diaz de, Maimone, Santo , Conant, Emily F.

Mayo Clinic

Journal of Breast Imaging | March 31, 2023 | Volume: 5 | Issue: 3 | Pages: 258-266

10.1093/jbi/wbad015 | PMID 38416890 Get It

Abstract Objective The purpose of this study is to assess the “real-world” impact of an artificial intelligence (AI) tool designed to detect breast cancer in digital breast tomosynthesis (DBT) screening exams following 12 months of utilization in a subspecialized academic breast center. Methods Following IRB approval, mammography audit reports, as specified in the BI-RADS atlas, were retrospectively generated for five radiologists reading at three locations during a 12-month time frame. One location had the AI tool (iCAD ProFound AI v2.0), and the other two locations did not. The co-primary endpoints were cancer detection rate (CDR) and abnormal interpretation rate (AIR). Secondary endpoints included positive predictive values (PPVs) for cancer among screenings with abnormal interpretations (PPV1) and for biopsies performed (PPV3). Odds ratios (OR) with two-sided 95% confidence intervals (CIs) summarized the impact of AI across radiologists using generalized estimating equations. Results Nonsignificant differences were observed in CDR, AIR, and PPVs. The CDR was 7.3 with AI and 5.9 without AI (OR 1.3, 95% CI: 0.9–1.7). The AIR was 11.7% with AI and 11.8% without AI (OR 1.0, 95% CI: 0.8–1.3). The PPV1 was 6.2% with AI and 5.0% without AI (OR 1.3, 95% CI: 0.97–1.7). The PPV3 was 33.3% with AI and 32.0% without AI (OR 1.1, 95% CI: 0.8–1.5). Conclusion Although we are unable to show statistically significant changes in CDR and AIR outcomes in the two groups, the results are consistent with prior reader studies. There is a nonsignificant trend toward improvement in CDR with AI, without significant increases in AIR.
Creation and preclinical evaluation of a novel mussel-inspired, biomimetic, bioactive bone graft scaffold: direct comparison with Infuse bone graft using a rat model of spinal fusion
Cottrill, Ethan , Pennington, Zach , Perdomo‐Pantoja, Alexander , Rajkovic, Christian , Lin, Jessica, Mageau, Ashlie, Stewart, Veronica , Sciubba, Daniel M. , Elisseeff, Jennifer H. , Pennington, Zach , Wolf, Matthew T. , Dirckx, Naomi , Ehresman, Jeff , Lin, Jessica, Maestas, David R. , Lambrechts, Dennis , Theodore, Nicholas , Witham, Timothy F.

Mayo Clinic

Journal of Neurosurgery: Spine | March 31, 2023 | Volume: 39 | Issue: 1 | Pages: 113-121

10.3171/2023.2.spine22936 | PMID 37021767 Get It

OBJECTIVE Infuse bone graft is a widely used osteoinductive adjuvant; however, the simple collagen sponge scaffold used in the implant has minimal inherent osteoinductive properties and poorly controls the delivery of the adsorbed recombinant human bone morphogenetic protein–2 (rhBMP-2). In this study, the authors sought to create a novel bone graft substitute material that overcomes the limitations of Infuse and compare the ability of this material with that of Infuse to facilitate union following spine surgery in a clinically translatable rat model of spinal fusion. METHODS The authors created a polydopamine (PDA)–infused, porous, homogeneously dispersed solid mixture of extracellular matrix and calcium phosphates (BioMim-PDA) and then compared the efficacy of this material directly with Infuse in the setting of different concentrations of rhBMP-2 using a rat model of spinal fusion. Sixty male Sprague Dawley rats were randomly assigned to each of six equal groups: 1) collagen + 0.2 µg rhBMP-2/side, 2) BioMim-PDA + 0.2 µg rhBMP-2/side, 3) collagen + 2.0 µg rhBMP-2/side, 4) BioMim-PDA + 2.0 μg rhBMP-2/side, 5) collagen + 20 µg rhBMP-2/side, and 6) BioMim-PDA + 20 µg rhBMP-2/side. All animals underwent posterolateral intertransverse process fusion at L4–5 using the assigned bone graft. Animals were euthanized 8 weeks postoperatively, and their lumbar spines were analyzed via microcomputed tomography (µCT) and histology. Spinal fusion was defined as continuous bridging bone bilaterally across the fusion site evaluated via µCT. RESULTS The fusion rate was 100% in all groups except group 1 (70%) and group 4 (90%). Use of BioMim-PDA with 0.2 µg rhBMP-2 led to significantly greater results for bone volume (BV), percentage BV, and trabecular number, as well as significantly smaller trabecular separation, compared with the use of the collagen sponge with 2.0 µg rhBMP-2. The same results were observed when the use of BioMim-PDA with 2.0 µg rhBMP-2 was compared with the use of the collagen sponge with 20 µg rhBMP-2. CONCLUSIONS Implantation of rhBMP-2–adsorbed BioMim-PDA scaffolds resulted in BV and bone quality superior to that afforded by treatment with rhBMP-2 concentrations 10-fold higher implanted on a conventional collagen sponge. Using BioMim-PDA (vs a collagen sponge) for rhBMP-2 delivery could significantly lower the amount of rhBMP-2 required for successful bone grafting clinically, improving device safety and decreasing costs.
Excessive Dynamic Airway Collapse Severity Scoring System
Lee‐Mateus, Alejandra Yu , Hernandez‐Rojas, Daniel , Pulipaka, Sai Priyanka , Garcia‐Saucedo, Juan C. , Majid, Adnan , Fernández-Bussy, Sebastián , Yu Lee-Mateus, Alejandra , Abia‐Trujillo, David , Saifi, Omran

Mayo Clinic

Journal of Bronchology & Interventional Pulmonology | March 31, 2023 | Volume: 30 | Issue: 3 | Pages: 200-206

10.1097/lbr.0000000000000918 | PMID 36999946 Get It

Background: Severe excessive dynamic airway collapse (EDAC) is defined as airway narrowing due to posterior wall protrusion into the airway lumen, >90%. We aimed to establish an overall severity score to assess severe EDAC and the need for subsequent intervention. Methods: A retrospective study of patients who underwent dynamic bronchoscopy for evaluation of expiratory central airway collapse between January 2019 and July 2021. A numerical value was given to each tracheobronchial segmental collapse: 0 points (<70%), 1 point (70% to 79%), 2 points (80% to 89%), and 3 points (>90%) to be added for an overall EDAC severity score per patient. We compared the score among patients who underwent stent trials (severe EDAC) and those who did not. Based on the receiver operating characteristics curve, a cutoff total score to predict severe EDAC was calculated. Results: One hundred fifty-eight patients were included. Patients were divided into severe (n = 60) and nonsevere (n = 98) EDAC. A cutoff of 9 as the total score had a sensitivity of 94% and a specificity of 74% to predict severe EDAC, based on an area under the curve 0.888 (95% CI: 0.84, 0.93; P < 0.001). Conclusion: Our EDAC Severity Scoring System was able to discern between severe and nonsevere EDAC by an overall score cutoff of 9, with high sensitivity and specificity for predicting severe disease and the need for further intervention, in our institution.
A Between-Sex Comparison of the Genomic Architecture of Asthma
Zein, Joe , Bazeley, Peter , Meyers, Deborah A. , Bleecker, Eugene R. , Gaston, Benjamin , Ortega, Victor E. , Ortega, Victor, Hu, Bo , Attaway, Amy

Mayo Clinic

American Journal of Respiratory Cell and Molecular Biology | March 31, 2023 | Volume: 68 | Issue: 4 | Pages: 456-458

10.1165/rcmb.2022-0430le | PMID 37000440 Get It

QIM23-138: Using the Electronic Health Record (EHR) to Capture Structured Oncology Data in Real-Time at the Point-of-Care: A Mayo Clinic Comprehensive Cancer Center (MCCCC) Pilot Study
Tevaarwerk, Amye J., Harlos, Elizabeth S., VanBebber, Heather L., Misel, Eli J., Nelson, Sacha A., Stockham, Abigail L. , Haddad, Tufia C. , Mandrekar, Sumithra J. , Maurer, Matthew J. , Vanbebber, Heather, Holton, Sara J., Alberts, Steven R. , McWilliams, Robert R.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2023 | Volume: 21 | Issue: 3.5 | Pages: QIM23-138

10.6004/jnccn.2022.7188 Get It

HSR23-097: Health-Related Quality of Life in Patients With Metastatic Basal Cell Carcinoma Treated With Cemiplimab: Analysis of a Phase 2 Open-Label Clinical Trial
Lewis, Karl D. , Quek, Ruben G.W. , Eroglu, Zeynep, Ivanescu, Cristina, Stratigos, Alexander , Sekulić, Aleksandar , Fury, Matthew G., Chen, Chieh-I, Inocencio, Timothy J. , LaFontaine, Patrick R. , Eroglu, Zeynep , Chang, Anne Lynn S. , Peris, Ketty

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2023 | Volume: 21 | Issue: 3.5 | Pages: HSR23-097

10.6004/jnccn.2022.7161 Get It

BIO23-023: Supporting the Capture of Structured Data for Patients With Cancer Using Cancer-Specific Note Templates
Carroll, Cibele Barbosa , Stietz, Chelsea, Pier, Jeffrey B., Lavitschke, Michael D., Mulkerin, Daniel , Sesto, Mary E. , Tevaarwerk, Amye J., Emamekhoo, Hamid , Pier, Jeff

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2023 | Volume: 21 | Issue: 3.5 | Pages: BIO23-023

10.6004/jnccn.2022.7233 Get It

CLO23-030: MC200402-Single-Arm Phase 2 Study of the FGFR Inhibitor Futibatinib (Futi) in Combination With Pembrolizumab (Pem) in Patients With FGF19 Expressing Advanced or Metastatic Hepatocellular Carcinoma (aHCC)
Larson, Joseph J. , McCue, Shaylene , Fernández-Zapico, Martín E. , Revzin, Alexander , Fonkoua, Lionel Aurelien Kankeu , Flickinger, Lynn M. , Jatoi, Aminah , Tran, Nguyen H. , Ou, Fang‐Shu , Mahipal, Amit , Graham, Rondell P. , Cleary, Sean P. , Bekaii‐Saab, Tanios , Borad, Mitesh J. , McWilliams, Robert R. , Wee, Wen

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 31, 2023 | Volume: 21 | Issue: 3.5 | Pages: CLO23-030

10.6004/jnccn.2022.7121 Get It

Treatment outcomes of extraskeletal Ewing sarcoma
Houdek, Matthew T. , Heidenreich, Mark J. , Ahmed, Safia K. , Petersen, Ivy A. , Rose, Peter S. , Allen-Rhoades, Wendy, Houdek, Matthew T , Allen‐Rhoades, Wendy , Siontis, Brittany L. , Robinson, Steven I.

Mayo Clinic

Journal of Surgical Oncology | March 31, 2023 | Volume: 128 | Issue: 1 | Pages: 105-110

10.1002/jso.27250 | PMID 36999583 Get It

AbstractPurposeExtraskeletal Ewing sarcoma (EES), is a rare soft tissue sarcoma. Treatment for EES commonly involves chemotherapy and surgical resection (ST) or less commonly combined chemotherapy, surgery, and radiotherapy (ST + RT). The purpose of the current study was to evaluate our institutional experience treating EES.MethodsWe reviewed 36 (18 males:18 females) patients (mean age 30 years) with a nonretroperitoneal/visceral EES treated with either ST (n = 24, 67%) or ST + RT (n = 12, 33%). All patients were treated with chemotherapy, most commonly vincristine, doxorubicin, cyclophosphamide/ifosfamide and etoposide (VDC/IE, n = 23, 66%) Radiotherapy was mostly delivered preoperatively (n = 9). The mean follow‐up was 8 years.ResultsThe 10‐year disease specific survival for patients was 78%, with no difference in the survival between patients in the ST versus the ST + RT groups (83% vs. 71%, p = 0.86). There was no difference in the 10‐year local recurrence (91% vs. 100%, p = 0.29) or metastatic free survival (87% vs. 75%, p = 0.45) between the ST and ST + RT groups.ConclusionThe results of the current study highlight the ability to achieve excellent local control with chemotherapy and surgery for EES. We recommend for multidisciplinary management of patients with EES, including chemotherapy and surgery, with use of radiotherapy if there is concern for a potentially close margin of resection.